Sign In
Buy PRE
Prenetics Global Earnings Calls
| Release date | May 14, 2026 |
| EPS estimate | -$0.490 |
| EPS actual | -$1.14 |
| EPS Surprise | -131.63% |
| Revenue estimate | 36.85M |
| Revenue actual | 36M |
| Revenue Surprise | -2.31% |
| Release date | Feb 18, 2026 |
| EPS estimate | -$0.490 |
| EPS actual | -$0.270 |
| EPS Surprise | 44.90% |
| Revenue estimate | 33.434M |
| Revenue actual | 36.6M |
| Revenue Surprise | 9.47% |
| Release date | Nov 10, 2025 |
| EPS estimate | -$0.550 |
| EPS actual | -$0.410 |
| EPS Surprise | 25.45% |
| Revenue estimate | 38.3M |
| Revenue actual | 23.555M |
| Revenue Surprise | -38.50% |
| Release date | Sep 12, 2025 |
| EPS estimate | -$0.710 |
| EPS actual | -$0.82 |
| EPS Surprise | -15.49% |
| Revenue estimate | 21.7M |
| Revenue actual | 17.68M |
| Revenue Surprise | -18.53% |
Last 4 Quarters for Prenetics Global
Below you can see how PRE performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Sep 12, 2025 |
| Price on release | $10.08 |
| EPS estimate | -$0.710 |
| EPS actual | -$0.82 |
| EPS surprise | -15.49% |
| Date | Price |
|---|---|
| Sep 08, 2025 | $9.39 |
| Sep 09, 2025 | $9.30 |
| Sep 10, 2025 | $10.08 |
| Sep 11, 2025 | $8.86 |
| Sep 12, 2025 | $10.08 |
| Sep 15, 2025 | $9.78 |
| Sep 16, 2025 | $9.49 |
| Sep 17, 2025 | $10.72 |
| Sep 18, 2025 | $10.84 |
| 4 days before | 7.32% |
| 4 days after | 7.59% |
| On release day | -2.93% |
| Change in period | 15.47% |
| Release date | Nov 10, 2025 |
| Price on release | $11.89 |
| EPS estimate | -$0.550 |
| EPS actual | -$0.410 |
| EPS surprise | 25.45% |
| Date | Price |
|---|---|
| Nov 04, 2025 | $12.81 |
| Nov 05, 2025 | $12.72 |
| Nov 06, 2025 | $12.35 |
| Nov 07, 2025 | $12.34 |
| Nov 10, 2025 | $11.89 |
| Nov 11, 2025 | $12.93 |
| Nov 12, 2025 | $13.87 |
| Nov 13, 2025 | $13.47 |
| Nov 14, 2025 | $12.20 |
| 4 days before | -7.15% |
| 4 days after | 2.61% |
| On release day | 8.75% |
| Change in period | -4.72% |
| Release date | Feb 18, 2026 |
| Price on release | $20.06 |
| EPS estimate | -$0.490 |
| EPS actual | -$0.270 |
| EPS surprise | 44.90% |
| Date | Price |
|---|---|
| Feb 11, 2026 | $21.40 |
| Feb 12, 2026 | $20.96 |
| Feb 13, 2026 | $21.97 |
| Feb 17, 2026 | $21.74 |
| Feb 18, 2026 | $20.06 |
| Feb 19, 2026 | $19.30 |
| Feb 20, 2026 | $17.05 |
| Feb 23, 2026 | $15.61 |
| Feb 24, 2026 | $15.90 |
| 4 days before | -6.26% |
| 4 days after | -20.74% |
| On release day | -3.79% |
| Change in period | -25.70% |
| Release date | May 14, 2026 |
| Price on release | $17.59 |
| EPS estimate | -$0.490 |
| EPS actual | -$1.14 |
| EPS surprise | -131.63% |
| Date | Price |
|---|---|
| May 08, 2026 | $16.16 |
| May 11, 2026 | $17.55 |
| May 12, 2026 | $17.99 |
| May 13, 2026 | $17.57 |
| May 14, 2026 | $17.59 |
| May 15, 2026 | $15.61 |
| May 18, 2026 | $14.54 |
| May 19, 2026 | $14.62 |
| May 20, 2026 | $15.47 |
| 4 days before | 8.85% |
| 4 days after | -12.05% |
| On release day | -11.26% |
| Change in period | -4.27% |
Prenetics Global Earnings Call Transcript Summary of Q1 2026
Prenetics (IM8) reported a strong Q1 2026 driven by its IM8 consumer health business. On a continuing operations basis Q1 revenue was $36M (up ~333% YoY), with IM8 contributing $33.8M and gross margin expanding to ~64%. Active subscribers were ~82,000 and servings delivered rose sequentially, with May monthly IM8 revenue tracking to ~$15.5M (implying ~$186M annualized recurring revenue). Management completed a global rollout of quarterly subscriptions, which materially increased new-customer AOV (to $240 in Q1) and improved cohort economics and payback. Management raised full-year IM8 revenue guidance to $190M–$210M and expects Q2 total revenue $46M–$48M (IM8 $44M–$46M). Margin expansion was explained by scale, supplier negotiations, favorable mix, and fulfillment efficiencies. Adjusted EBITDA guidance remains effectively unchanged (management emphasized disciplined marketing investment to drive international subscription rollout). The company holds ~ $147M in financial resources after selling its Bitcoin position and plans to deploy cash for buybacks, accelerated DTC marketing, product launches (hydration, creatine, kids gummies planned for Q4), and international expansion. Key strategic moats cited: athlete equity-aligned partnerships (Beckham, Sabalenka, Giannis, Inter Miami), RCT-backed science (existing and upcoming trials), and an AI-driven ad/creative engine scaling across Meta and expanding to TikTok/YouTube/AppLovin. Management emphasized that new SKUs and channel diversification are incremental upside not included in guidance.
